1-Feb-2023
Edison report: Reinvestment period with increased R&D focus
1-Nov-2022
Edison report: Q1 23 cash flows in line with our estimates
28-Oct-2022
New melanoma breakthrough by Kazia could potentially save thousands of lives
10-Oct-2022
Edison report: PNOC022 trial expanded
5-Sep-2022
Edison report: Doubling down on clinical development
8-Aug-2022
Interim data from MSKCC study
1-Aug-2022
GBM Agile Update
20-Jul-2022
Kazia recognises GBM Awareness Day 2022 as it expands clinical trial activity in Europe and US
12-Jul-2022
Kazia launches new SAB
17-Jun-2022
FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT
14-Jun-2022
Kazia paxalisib preclinical DIPG data released at IPSNO
8-Jun-2022
Kazia's Alliance study progresses to expansion phase
3-Jun-2022
Kazia presents final PII data at ASCO
31-May-2022
GBM Agile opens to paxalisib in Europe
24-May-2022
Edison Research: Deep Dive into Childhood Brain Cancer
23-May-2022
Kazia to present at investor conferences hosted by HC Wainwright and LD Micro
17-May-2022
Kazia marks DIPG Awareness Day
17-May-2022
Interview with Dr Matt Dun for World DIPG Awareness Day
29-Apr-2022
Kazia to present at ASCO
8-Apr-2022
Kazia presents preclinical data for paxalisib at AACR
8-Apr-2022
Kazia presents on EVT801 at AACR
21-Mar-2022
Kazia to present at two conferences
28-Feb-2022
First patient into Cornell keto study
31-Jan-2022
Quarterly Activities Report And Appendix 4c
19-Jan-2022
Kazia Corporate Presentation
7-Jan-2022
Kazia Therapeutics To Present At Hc Wainwright Bioconnect Conference
13-Dec-2021
Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer
3-Dec-2021
Kazia Announces Positive Final Data From Phase Ii Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
29-Nov-2021
Gbm Agile Opens To Paxalisib In Canada
15-Nov-2021
Kazia Therapeutics Appoints John Friend, Md, As Chief Medical Officer
11-Nov-2021
Pnoc Study In Childhood Brain Cancer Enrols First Patient
10-Nov-2021
Kazia Annual General Meeting Results
4-Nov-2021
Kazia Annual General Meeting Results
29-Oct-2021
Quarterly Activities Report And Appendix 4c
10-Sep-2021
Kazia Therapeutics To Present At Hc Wainwright 23rd Annual Global Investment Conference
2-Sep-2021
Evt801 Phase I Study Receives Full Regulatory Approval
30-Jul-2021
Quarterly Activities Report And Appendix 4c
21-Jul-2021
Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day
30-Jun-2021
Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs
24-Jun-2021
Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036
15-Jun-2021
Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma
7-Jun-2021
Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient
19-Apr-2021
Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se
29-Mar-2021
Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company
1-Mar-2021
Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab
7-Jan-2021
Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm
20-Dec-2020
Kazia Therapeutics Limited Appendix 4D Half-year report